Evaluation of Dose-response, Pharmacodynamic and Pharmacokinetic Bioequivalence of Filgrastim in Healthy Male Volunteers After Single and Multiple-dose Subcutaneous Administration of the Test Injectable Formulation BK0023 vs. Neupogen®

PHASE1CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Healthy Male Subjects
Interventions
DRUG

Filgrastim test

0.3 mg/mL injectable solution in 1 mL vials Manufacturer (Drug Substance): Eurogenetec S.A., B-4102 Seraing, Belgium Manufacturer (Drug Product): Areta International S.r.l., I-21040 Gerenzano, Italy Batch release: Areta International S.r.l., I-21040 Gerenzano, Italy Route of administration: subcutaneous

DRUG

Filgrastim reference

"0.3 mg/mL injectable solution in 1 mL vials Licensed owner: Dompé farmaceutici S.p.A., Milan, Italy Manufacturer (Drug Product): Hoffmann - La Roche Ltd., Basel, Switzerland and Amgen Manufacturing Limited, Puertorico.~Batch release: Amgen Europe B.V., Breda, Netherlands Route of administration: subcutaneous"

Trial Locations (1)

6864

CROSS Research SA, Arzo

All Listed Sponsors
collaborator

Cross Research S.A.

INDUSTRY

collaborator

Nerviano Medical Sciences

INDUSTRY

collaborator

AAI Deutschland GmbH & Co. KG

OTHER

collaborator

Gife S.A.

OTHER

lead

Bio-ker S.r.l.

INDUSTRY

NCT01933971 - Evaluation of Dose-response, Pharmacodynamic and Pharmacokinetic Bioequivalence of Filgrastim in Healthy Male Volunteers After Single and Multiple-dose Subcutaneous Administration of the Test Injectable Formulation BK0023 vs. Neupogen® | Biotech Hunter | Biotech Hunter